Bioenvision Receives Notification from Nasdaq Regarding Removal of ''E'' from Trading Symbol
June 30 2005 - 7:00AM
Business Wire
Bioenvision, Inc. (Nasdaq: BIVN) today announced that the Nasdaq
Listings Qualifications Panel has approved its request for
continued listing on the Nasdaq National Market and advises that
the fifth character "E" will be removed from Bioenvision's trading
symbol effective on the opening of trading on Friday, July 1, 2005.
As noted in prior press releases, the "E" had been added to the
Bioenvision trading symbol because the Company had not been in
compliance with Nasdaq's listing standards as a result of a delay
in filing its quarterly report on Form 10-QSB for the quarter ended
March 31, 2005. The Form 10-QSB was subsequently filed on June 29,
2005. As a result, the Nasdaq Listings Qualifications Panel has
determined that the Company now has satisfied its filing
requirements and has evidenced compliance with all other
requirements necessary for continued listing on the Nasdaq National
Market. About Bioenvision Bioenvision's primary focus is the
acquisition, development and distribution of compounds and
technologies for the treatment of cancer. Bioenvision has a broad
pipeline of products for the treatment of cancer, including:
Clofarabine (in co-development with Genzyme Corporation),
Modrenal(R) (for which Bioenvision has obtained regulatory approval
for marketing in the United Kingdom for the treatment of
post-menopausal breast cancer following relapse to initial hormone
therapy), and other products in clinical trials. Bioenvision is
also developing anti-infective technologies, including the OLIGON
technology; an advanced biomaterial that has been incorporated into
various FDA approved medical devices. For more information on
Bioenvision please visit our Web site at www.bioenvision.com.
Certain statements contained herein are "forward-looking"
statements (as such term is defined in the Private Securities
Litigation Reform Act of 1995). Because these statements include
risks and uncertainties, actual results may differ materially from
those expressed or implied by such forward-looking statements.
Specifically, factors that could cause actual results to differ
materially from those expressed or implied by such forward-looking
statements include, but are not limited to: risks associated with
preclinical and clinical developments in the biopharmaceutical
industry in general and in Bioenvision's compounds under
development in particular; the potential failure of Bioenvision's
compounds under development to prove safe and effective for
treatment of disease; uncertainties inherent in the early stage of
Bioenvision's compounds under development; failure to successfully
implement or complete clinical trials; failure to receive marketing
clearance from regulatory agencies for our compounds under
development; acquisitions, divestitures, mergers, licenses or
strategic initiatives that change Bioenvision's business, structure
or projections; the development of competing products;
uncertainties related to Bioenvision's dependence on third parties
and partners; and those risks described in Bioenvision's filings
with the SEC. Bioenvision disclaims any obligation to update these
forward-looking statements.
Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From Jul 2023 to Jul 2024